U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2Cl.Pt
Molecular Weight 265.99
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PLATINOUS CHLORIDE

SMILES

[Cl-].[Cl-].[Pt++]

InChI

InChIKey=CLSUSRZJUQMOHH-UHFFFAOYSA-L
InChI=1S/2ClH.Pt/h2*1H;/q;;+2/p-2

HIDE SMILES / InChI
Molecular Formula Pt
Molecular Weight 195.084
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.drugbank.ca/drugs/DB00515 | https://www.ncbi.nlm.nih.gov/pubmed/27736024 | https://www.ncbi.nlm.nih.gov/pubmed/25159039

There is no available sources on the medical use of platinum iodide. The salt is insoluble.

CNS Activity

CNS Non-penetrant
1014
Curator's Comment: With the injection of cisplatin into mice 3 h after the LPS treatment, platinum was detected in the CCR during the 7 days after the injection, while platinum was not detected in the CCR of cisplatin-injected mice without LPS pretreatment and of mice simultaneous treated with cisplatin and LPS.

Originator

Approval Year

1978
87
Targets

Targets

Primary TargetPharmacologyConditionPotency
DNA
278
Target ID: CHEMBL2311221
Crosslinking Agent
81
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
CISPLATIN

Approved Use

Cisplatin injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. Metastatic Ovarian Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Cisplatin injection and cyclophosphamide. Cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin injection therapy. Advanced Bladder Cancer Cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy.

Launch Date

1978
Primary
Approved
8429
CISPLATIN

Approved Use

Cisplatin injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. Metastatic Ovarian Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Cisplatin injection and cyclophosphamide. Cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin injection therapy. Advanced Bladder Cancer Cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy.

Launch Date

1978
Primary
Approved
8429
CISPLATIN

Approved Use

Cisplatin injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. Metastatic Ovarian Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Cisplatin injection and cyclophosphamide. Cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin injection therapy. Advanced Bladder Cancer Cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy.

Launch Date

1978
Primary
Phase IV
63
CISPLATIN

Approved Use

Cisplatin injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. Metastatic Ovarian Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Cisplatin injection and cyclophosphamide. Cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin injection therapy. Advanced Bladder Cancer Cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy.

Launch Date

1978
PubMed

PubMed

TitleDatePubMed
Platinum(II) chloride-catalyzed stereoselective domino enyne isomerization/Diels-Alder reaction.
2010 Nov 19
Platinum-catalyzed one-pot alkenylation of aldehydes using alkynes and triethylsilane: dual catalysis by platinum(II) chloride.
2013 Nov 1
Synthesis of tetracyclic chromenones via platinum(II) chloride catalysed cascade cyclization of enediyne-enones.
2014 Feb 28
Retrospective Analysis of the Risk Factors for Grade IV Neutropenia in Oesophageal Cancer Patients Treated with a Docetaxel, Cisplatin, and 5-Fluorouracil Regimen.
2017
Patents

Patents

WO2017059434
4

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 16 09:45:13 GMT 2023
Edited
by admin
on Sat Dec 16 09:45:13 GMT 2023
Record UNII
896SQ4TDHW
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PLATINOUS CHLORIDE
HSDB   MI   WHO-DD  
Common Name English
PLATINUM(II) CHLORIDE
Systematic Name English
PLATINOUS DICHLORIDE
Common Name English
PLATINOUS CHLORIDE [HSDB]
Common Name English
Platinous chloride [WHO-DD]
Common Name English
PLATINUM CHLORIDE (PTCL2)
Common Name English
PLATINOUS CHLORIDE [MI]
Common Name English
PLATINUM DICHLORIDE
Systematic Name English
PLATINUM(II) DICHLORIDE
Systematic Name English
Code System Code Type Description
FDA UNII
896SQ4TDHW
Created by admin on Sat Dec 16 09:45:13 GMT 2023 , Edited by admin on Sat Dec 16 09:45:13 GMT 2023
PRIMARY
WIKIPEDIA
Platinum(II) chloride
Created by admin on Sat Dec 16 09:45:13 GMT 2023 , Edited by admin on Sat Dec 16 09:45:13 GMT 2023
PRIMARY
CHEBI
49801
Created by admin on Sat Dec 16 09:45:13 GMT 2023 , Edited by admin on Sat Dec 16 09:45:13 GMT 2023
PRIMARY
ECHA (EC/EINECS)
233-034-1
Created by admin on Sat Dec 16 09:45:13 GMT 2023 , Edited by admin on Sat Dec 16 09:45:13 GMT 2023
PRIMARY
MERCK INDEX
m8913
Created by admin on Sat Dec 16 09:45:13 GMT 2023 , Edited by admin on Sat Dec 16 09:45:13 GMT 2023
PRIMARY Merck Index
PUBCHEM
2770
Created by admin on Sat Dec 16 09:45:13 GMT 2023 , Edited by admin on Sat Dec 16 09:45:13 GMT 2023
PRIMARY
HSDB
6340
Created by admin on Sat Dec 16 09:45:13 GMT 2023 , Edited by admin on Sat Dec 16 09:45:13 GMT 2023
PRIMARY
EPA CompTox
DTXSID6064901
Created by admin on Sat Dec 16 09:45:13 GMT 2023 , Edited by admin on Sat Dec 16 09:45:13 GMT 2023
PRIMARY
SMS_ID
100000184192
Created by admin on Sat Dec 16 09:45:13 GMT 2023 , Edited by admin on Sat Dec 16 09:45:13 GMT 2023
PRIMARY
CAS
10025-65-7
Created by admin on Sat Dec 16 09:45:13 GMT 2023 , Edited by admin on Sat Dec 16 09:45:13 GMT 2023
PRIMARY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966